Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Opening Vaccines Launch Facility

About the Symposium

The speakers include: Bruno Bruins - Minister for Medical Care and Sport of the Netherlands, Pierre Meulien of the EU’s Innovative Medicines Initiative (IMI), Jayasree K. Iyer of the Access to Vaccines Index (ATVI) and Ab Osterhaus of the Research Center for Emerging Infections and Zoonoses (RIZ) in Hannover.

Inspiring and engaging presentations and panel discussions will highlight why it is important to “Invest locally, to protect globally”, addressing topics such as the central role of prevention and the role of vaccines specifically in transforming human health and the importance of global and regional collaborations in pandemic preparedness initiatives.

View the complete program of the symposium and the speakers.

The Vaccines Launch Facility

The new facility in Leiden (near Amsterdam) is set up to make a profound, long-term contribution to global health. The facility is constructed for production of late-stage (Phase 3) clinical trial supplies for Janssen’s current investigational vaccines, including vaccines targeting HIV, Respiratory Syncytial Virus (RSV), Ebola, and a universal Influenza vaccine.

Pending regulatory approvals, the facility will also be ready to manufacture the first batches of these vaccines for real-world use.

 

Venue

The opening event will take place at the Corpus Congress Centre, located only 500 meters away from the new Vaccines Launch Facility.

Address

Willem Einthovenstraat 1, 2342 BH Oegstgeest, the Netherlands.
If you need any recommendations for travel to and from the venue, or for accommodation near the venue, feel free to reach out to us.


About Us

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

In the Netherlands, Janssen has 2100 employees across sites in Breda, Leiden and Woerden. They cover the full spectrum of activities from research & development and supply chain to commercial. According to Technisch Weekblad, Janssen is the largest Pharma R&D investor in the Netherlands and the fourth largest R&D investor across all sectors.

 

Please feel free to reach out to us, if you have any question.

 

© Janssen-Cilag B.V. - PHNL/JVA/0918/0002a date of preparation 10 October 2018